TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories

Sally Land, Philip Cunningham, Jialun Zhou, Kevin Frost, David Katzenstein, Rami Kantor, Yi Ming Arthur Chen, Shinichi Oka, Allison DeLong, David Sayer, Jeffery Smith, Elizabeth M. Dax, Matthew Law

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The TREAT Asia (Therapeutics, Research, Education, and AIDS Training in Asia) Network is building capacity for Human Immunodeficiency Virus Type-1 (HIV-1) drug resistance testing in the region. The objective of the TREAT Asia Quality Assessment Scheme - designated TAQAS - is to standardize HIV-1 genotypic resistance testing (HIV genotyping) among laboratories to permit rigorous comparison of results from different clinics and testing centres. TAQAS has evaluated three panels of HIV-1-positive plasma from clinical material or low-passage, culture supernatant for up to 10 Asian laboratories. Laboratory participants used their standard protocols to perform HIV genotyping. Assessment was in comparison to a target genotype derived from all participants and the reference laboratory's result. Agreement between most participants at the edited nucleotide sequence level was high (>98%). Most participants performed to the reference laboratory standard in detection of drug resistance mutations (DRMs). However, there was variation in the detection of nucleotide mixtures (0-83%) and a significant correlation with the detection of DRMs (p < 0.01). Interpretation of antiretroviral resistance showed ∼70% agreement among participants when different interpretation systems were used but >90% agreement with a common interpretation system, within the Stanford University Drug Resistance Database. Using the principles of external quality assessment and a reference laboratory, TAQAS has demonstrated high quality HIV genotyping results from Asian laboratories.

Original languageEnglish
Pages (from-to)185-193
Number of pages9
JournalJournal of Virological Methods
Volume159
Issue number2
DOIs
Publication statusPublished - Aug 1 2009
Externally publishedYes

Fingerprint

HIV
HIV-1
Drug Resistance
Pharmaceutical Databases
Therapeutic Human Experimentation
Capacity Building
Mutation
Acquired Immunodeficiency Syndrome
Nucleotides
Genotype
Education

Keywords

  • Drug resistance
  • Genotyping
  • HIV
  • Quality assessment
  • TAQAS

ASJC Scopus subject areas

  • Virology

Cite this

TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. / Land, Sally; Cunningham, Philip; Zhou, Jialun; Frost, Kevin; Katzenstein, David; Kantor, Rami; Chen, Yi Ming Arthur; Oka, Shinichi; DeLong, Allison; Sayer, David; Smith, Jeffery; Dax, Elizabeth M.; Law, Matthew.

In: Journal of Virological Methods, Vol. 159, No. 2, 01.08.2009, p. 185-193.

Research output: Contribution to journalArticle

Land, S, Cunningham, P, Zhou, J, Frost, K, Katzenstein, D, Kantor, R, Chen, YMA, Oka, S, DeLong, A, Sayer, D, Smith, J, Dax, EM & Law, M 2009, 'TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories', Journal of Virological Methods, vol. 159, no. 2, pp. 185-193. https://doi.org/10.1016/j.jviromet.2009.03.016
Land, Sally ; Cunningham, Philip ; Zhou, Jialun ; Frost, Kevin ; Katzenstein, David ; Kantor, Rami ; Chen, Yi Ming Arthur ; Oka, Shinichi ; DeLong, Allison ; Sayer, David ; Smith, Jeffery ; Dax, Elizabeth M. ; Law, Matthew. / TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. In: Journal of Virological Methods. 2009 ; Vol. 159, No. 2. pp. 185-193.
@article{b313b0b618794bc79f4d88b7730fce88,
title = "TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories",
abstract = "The TREAT Asia (Therapeutics, Research, Education, and AIDS Training in Asia) Network is building capacity for Human Immunodeficiency Virus Type-1 (HIV-1) drug resistance testing in the region. The objective of the TREAT Asia Quality Assessment Scheme - designated TAQAS - is to standardize HIV-1 genotypic resistance testing (HIV genotyping) among laboratories to permit rigorous comparison of results from different clinics and testing centres. TAQAS has evaluated three panels of HIV-1-positive plasma from clinical material or low-passage, culture supernatant for up to 10 Asian laboratories. Laboratory participants used their standard protocols to perform HIV genotyping. Assessment was in comparison to a target genotype derived from all participants and the reference laboratory's result. Agreement between most participants at the edited nucleotide sequence level was high (>98{\%}). Most participants performed to the reference laboratory standard in detection of drug resistance mutations (DRMs). However, there was variation in the detection of nucleotide mixtures (0-83{\%}) and a significant correlation with the detection of DRMs (p < 0.01). Interpretation of antiretroviral resistance showed ∼70{\%} agreement among participants when different interpretation systems were used but >90{\%} agreement with a common interpretation system, within the Stanford University Drug Resistance Database. Using the principles of external quality assessment and a reference laboratory, TAQAS has demonstrated high quality HIV genotyping results from Asian laboratories.",
keywords = "Drug resistance, Genotyping, HIV, Quality assessment, TAQAS",
author = "Sally Land and Philip Cunningham and Jialun Zhou and Kevin Frost and David Katzenstein and Rami Kantor and Chen, {Yi Ming Arthur} and Shinichi Oka and Allison DeLong and David Sayer and Jeffery Smith and Dax, {Elizabeth M.} and Matthew Law",
year = "2009",
month = "8",
day = "1",
doi = "10.1016/j.jviromet.2009.03.016",
language = "English",
volume = "159",
pages = "185--193",
journal = "Journal of Virological Methods",
issn = "0166-0934",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories

AU - Land, Sally

AU - Cunningham, Philip

AU - Zhou, Jialun

AU - Frost, Kevin

AU - Katzenstein, David

AU - Kantor, Rami

AU - Chen, Yi Ming Arthur

AU - Oka, Shinichi

AU - DeLong, Allison

AU - Sayer, David

AU - Smith, Jeffery

AU - Dax, Elizabeth M.

AU - Law, Matthew

PY - 2009/8/1

Y1 - 2009/8/1

N2 - The TREAT Asia (Therapeutics, Research, Education, and AIDS Training in Asia) Network is building capacity for Human Immunodeficiency Virus Type-1 (HIV-1) drug resistance testing in the region. The objective of the TREAT Asia Quality Assessment Scheme - designated TAQAS - is to standardize HIV-1 genotypic resistance testing (HIV genotyping) among laboratories to permit rigorous comparison of results from different clinics and testing centres. TAQAS has evaluated three panels of HIV-1-positive plasma from clinical material or low-passage, culture supernatant for up to 10 Asian laboratories. Laboratory participants used their standard protocols to perform HIV genotyping. Assessment was in comparison to a target genotype derived from all participants and the reference laboratory's result. Agreement between most participants at the edited nucleotide sequence level was high (>98%). Most participants performed to the reference laboratory standard in detection of drug resistance mutations (DRMs). However, there was variation in the detection of nucleotide mixtures (0-83%) and a significant correlation with the detection of DRMs (p < 0.01). Interpretation of antiretroviral resistance showed ∼70% agreement among participants when different interpretation systems were used but >90% agreement with a common interpretation system, within the Stanford University Drug Resistance Database. Using the principles of external quality assessment and a reference laboratory, TAQAS has demonstrated high quality HIV genotyping results from Asian laboratories.

AB - The TREAT Asia (Therapeutics, Research, Education, and AIDS Training in Asia) Network is building capacity for Human Immunodeficiency Virus Type-1 (HIV-1) drug resistance testing in the region. The objective of the TREAT Asia Quality Assessment Scheme - designated TAQAS - is to standardize HIV-1 genotypic resistance testing (HIV genotyping) among laboratories to permit rigorous comparison of results from different clinics and testing centres. TAQAS has evaluated three panels of HIV-1-positive plasma from clinical material or low-passage, culture supernatant for up to 10 Asian laboratories. Laboratory participants used their standard protocols to perform HIV genotyping. Assessment was in comparison to a target genotype derived from all participants and the reference laboratory's result. Agreement between most participants at the edited nucleotide sequence level was high (>98%). Most participants performed to the reference laboratory standard in detection of drug resistance mutations (DRMs). However, there was variation in the detection of nucleotide mixtures (0-83%) and a significant correlation with the detection of DRMs (p < 0.01). Interpretation of antiretroviral resistance showed ∼70% agreement among participants when different interpretation systems were used but >90% agreement with a common interpretation system, within the Stanford University Drug Resistance Database. Using the principles of external quality assessment and a reference laboratory, TAQAS has demonstrated high quality HIV genotyping results from Asian laboratories.

KW - Drug resistance

KW - Genotyping

KW - HIV

KW - Quality assessment

KW - TAQAS

UR - http://www.scopus.com/inward/record.url?scp=67349098439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349098439&partnerID=8YFLogxK

U2 - 10.1016/j.jviromet.2009.03.016

DO - 10.1016/j.jviromet.2009.03.016

M3 - Article

VL - 159

SP - 185

EP - 193

JO - Journal of Virological Methods

JF - Journal of Virological Methods

SN - 0166-0934

IS - 2

ER -